Therapeutic Specialties Page
Explore our Therapeutic Area Services and tap into unmatched therapeutic area expertise in Clinical Development. Find our full list of service areas here.
Global Health Page
Certara Global Health (CGH) brings together talent, technology, and software to accelerate the development of medicines for those that need them most.
Upcoming Simcyp Workshops Page
Enhance your drug development skills with Certara’s Simcyp PBPK workshops. View our upcoming workshops.
Payment Page
Pediatric Practice Page
Certara's Pediatric MIDD Accelerator advances efficient and reliable pediatric drug development processes that optimize dosing and get critical medicines to children faster.
Rare and Neglected Diseases Page
Overcome rare disease drug development challenges with our proven biosimulation software & expertise, supporting 90% of FDA orphan drug approvals since 2014.
Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology Publication
Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re‐targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging...
The Research to Accelerate Cures and Equity (RACE) for Children Act: Changing the Landscape of Pediatric Cancer Drug Development Blog Post
3 key tips to set your pediatric program up for success with the RACE for Children Act by Lynne Georgopoulos, RN, MSHS, RAC, Vice President, Regulatory Strategy at Certara On August 18, 2020, the Research to Accelerate Cures and Equity...
Salvaging CNS Clinical Trials Halted Due to COVID‐19 Publication
The coronavirus disease 2019 (COVID‐19) pandemic has halted many ongoing central nervous system (CNS) clinical trials, especially in Alzheimer’s disease. These long‐duration trials involve many stakeholders, especially the patients and their family members, who have demonstrated their commitment to developing...
